With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News

NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Todays Updates

Rural Accountable Care Organizations: Better Diabetes Care

Participation in accountable care organizations shows better diabetes care outcomes for patients in rural areas than for those in urban settings.

Sex Disparity Seen in Response to Growth Therapy in 21-OHD

In patients with classical 21-hydroxylase deficiency, growth-promoting therapies have variable effects: They increase final height relative to midparental height in boys but not in girls.

Higher Relative Fat Mass Is Linked With Chronic Diarrhea

Higher relative fat mass is associated with increased odds of having chronic diarrhea, although the measure alone shows limited ability to predict risk.

Diabetes in Mothers Tied to Epilepsy Risk in Offspring

Risk rises with all three types of diabetes mellitus but mostly with type 2.

Managing Constipation in Patients on GLP-1s

As GLP-1 use rise, constipation remains a leading cause of discontinuation. Experts offer practical strategies for prevention and management.

Dapagliflozin Can Reduce Liver Fat in Diabetes

In patients with type 2 diabetes, 12 months of dapagliflozin therapy is significantly associated with reduced liver fat, independent of weight loss or other metabolic benefits.

Diabetes Remission Is Possible, but There’s Not Just One Way

Physicians must deploy specific tools in specific ways at specific times — adding to the time-consuming treatment costs.

Todays Updates

Rural Accountable Care Organizations: Better Diabetes Care

Participation in accountable care organizations shows better diabetes care outcomes for patients in rural areas than for those in urban settings.

Sex Disparity Seen in Response to Growth Therapy in 21-OHD

In patients with classical 21-hydroxylase deficiency, growth-promoting therapies have variable effects: They increase final height relative to midparental height in boys but not in girls.

Higher Relative Fat Mass Is Linked With Chronic Diarrhea

Higher relative fat mass is associated with increased odds of having chronic diarrhea, although the measure alone shows limited ability to predict risk.

Diabetes in Mothers Tied to Epilepsy Risk in Offspring

Risk rises with all three types of diabetes mellitus but mostly with type 2.

Managing Constipation in Patients on GLP-1s

As GLP-1 use rise, constipation remains a leading cause of discontinuation. Experts offer practical strategies for prevention and management.

Dapagliflozin Can Reduce Liver Fat in Diabetes

In patients with type 2 diabetes, 12 months of dapagliflozin therapy is significantly associated with reduced liver fat, independent of weight loss or other metabolic benefits.

Diabetes Remission Is Possible, but There’s Not Just One Way

Physicians must deploy specific tools in specific ways at specific times — adding to the time-consuming treatment costs.

Latest News

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

News All Time

Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers Marco Meglio

Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.

CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis Marco Meglio

New phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing

Late-Breaking CHOICE 2 Data Indicate Alteplase Displayed Improved Stroke Recovery Louie Pasculli

Adding intra-arterial alteplase after successful endovascular thrombectomy significantly improved 90-day functional outcomes in patients with large-vessel acute ischemic stroke, according to late-breaking data from the phase 3 CHOICE2 trial.

Subgroup Signals Emerge for rFVIIa in Acute Intracerebral Hemorrhage in Phase 3 FASTEST Trial Marco Meglio

FASTEST finds rFVIIa curbs ICH bleeding fast but adds clot risk; ultra-early and spot-sign patients show promise as Part 2 continues.

Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis Marco Meglio

Real-world phase 4 data show cladribine keeps relapse rates low and safety steady in relapsing MS patients, including those 65+.

Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis Noah Stansfield

The analysis included 280 patients from CLARIFY-MS extension and 219 patients from MAGNIFY-MS extension, a total of 499 patients with at least 4 years of follow-up.

Real-World Data Analysis Highlight Clinical Profiles and Inebilizumab Use Patterns in NMOSD Isabella Ciccone, MPH

A cohort analysis, presented at ACTRIMS 2026, provided insight into the clinical characteristics, disease burden, and treatment sequencing of patients with neuromyelitis optica spectrum disorder treated with inebilizumab.

CREST-2 Substudy Shows No Cognitive Benefit of Carotid Revascularization in Asymptomatic Carotid Stenosis Isabella Ciccone, MPH

Late-breaking data from a substudy of the CREST-2 trial revealed that carotid revascularization did not show greater improvements in cognitive function compared with intensive medical management.

Biomarker Data Across Studies Support Disease-Targeted Effects of Valiltramiprosate Marco Meglio

Newly reported data showed that oral valiltramiprosate lowers p-tau217 and links to cognitive and brain-volume benefits in early Alzheimer disease.

NeuroVoices: Benjamin Tolchin, MD, FAAN, on First-Ever AAN Guidelines for Functional Seizures Marco Meglio

The director of the Center for Clinical Ethics at Yale New Haven Health discussed the rationale behind the newly published AAN guidelines on functional seizures, outlining diagnostic priorities, evidence-based treatment recommendations, and key gaps.

National Women Physicians Day: Learning, Leading, and Lifting Others in Neurology Marco Meglio, Merit Cudkowicz, MD, MSc

ALS expert Merit Cudkowicz, MD, MSc, provided thoughts for National Women Physicians Day, reflecting on resilience in ALS research, the power of mentorship, and how leadership and advocacy can shape a meaningful career in neurology.

National Women Physicians Day: Perspectives From Riley Bove, MD Louie Pasculli, Riley Bove, MD

Riley Bove, MD, MS, associate professor of neurology at the University of California San Francisco, shares her personal view on National Women’s Physician’s and why it’s important for clinicians and patients in the field.

Women Physicians Day 2026: Prioritizing Whole-Person Care for Women With Movement Disorders Isabella Ciccone, MPH, Jill Farmer, DO, MPH, FCPP, DipABLM, Kelly Papesh, DNP, APRN, FNP-C, CMRD, Madhureeta Achari, MD, Joanna Dearlove, MD

As part of National Women Physicians Day, a group of women clinicians discussed various topics in the care for women with movement disorders.

National Women Physicians Day: Insights From Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO, Louie Pasculli

Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO, director of the JS Sonshine Center, shares her personal view on National Women Physician’s and why it’s important for clinicians and patients in the field.

National Women Physicians Day: Women Driving Change in Neurology Louie Pasculli

In honor of National Women Physician’s Day, the NeurologyLive® team highlighted recent studies on women transforming neurologic care and advancing women’s health.

VMAT2 Inhibitor NBI-1065890 Heads to Phase 2 Study in Tardive Dyskinesia Marco Meglio

Neurocrine Biosciences launches a Phase 2 trial for NBI-1065890, targeting tardive dyskinesia with promising new treatment options.

Recommended News For You

The amount of liver tissue removed during gallbladder surgery has no discernible impact on overall survival.

Admissions, medical colleges, fees, and eligibility requirements information for the DNB Post Diploma in Radiation Oncology.

Dr. Prerana S. Nesargi's message for Childhood Cancer Awareness Month 2023 is to increase understanding of pediatric oncology.

Housing aid linked to lower medical financial hardship among US renters with cancer

Loneliness and social isolation linked to heightened risk of death in those with cancer

Analysis of 2021 data shows new cancer diagnoses did not rebound as expected following pandemic

Genetics and therapy type determine second cancer risk after childhood treatment, study finds

Recommended Articles For You

Tumor Evolution: Signaling, Plasticity, and Intratumor Heterogeneity in Cancer 

Exploring the Pleomorphic Adenoma: A Unique and Varied Tumor 

Sound Waves and Self-Destruction: A Promising Nanotech Weapon in the Fight Against Cancer 

Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Housing aid linked to lower medical financial hardship among US renters with cancer

2.

Review looks at potential treatment targets in the tumor microenvironment.

3.

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.

4.

Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.

5.

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

1.

Understanding Hidrocystoma: Symptoms, Causes, and Treatment Options 

2.

All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment

3.

Breaking Down Leukocytoclastic Vasculitis: Causes, Symptoms and Treatment

4.

Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options 

5.

Clinical Analysis of Prostate Cancer

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

2.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

3.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

5.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot